首页> 外文期刊>Journal of Medicinal Chemistry >Novel Lead Structures for p38 MAP Kinase via FieldScreen Virtual Screening
【24h】

Novel Lead Structures for p38 MAP Kinase via FieldScreen Virtual Screening

机译:通过FieldScreen虚拟筛选获得p38 MAP激酶的新型先导结构

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

p38 MAP kinase has received considerable interest in the pharmaceutical industry and remains a valid and interesting target for the treatment of inflammation. To discover novel p38 inhibitors, we applied the ligand-based virtual screening technique, FieldScreen, to 1.2 million commercially available compounds. Fifty-eight diverse compounds were selected for biological analysis, using molecular field similarity to known inhibitors, while explicitly removing any structure that shared a scaffold with previously reported p38 inhibitors. Of these, 11 (19%) showed >= 20% inhibition of p38 at 10 mu M. We chose to prepare analogues of two distinct chemical series resulting in a potential lead compound with pIC(50) of 6.4. Modeling of SAR using FieldAlign, a ligand alignment protocol, was used to rationalize the SAR of the series of thiadiazole based inhibitors.
机译:p38 MAP激酶已在制药行业引起广泛关注,并且仍然是治疗炎症的有效且有趣的靶标。为了发现新型的p38抑制剂,我们将基于配体的虚拟筛选技术FieldScreen应用于120万种市售化合物。利用与已知抑制剂的分子场相似性,选择了58种多样的化合物进行生物学分析,同时明确去除了与先前报道的p38抑制剂共享支架的任何结构。其中11个(19%)在10μM时显示p38抑制率> = 20%。我们选择制备两个不同化学系列的类似物,导致潜在的铅化合物的pIC(50)为6.4。使用配体比对方案FieldAlign对SAR进行建模可合理化一系列基于噻二唑的抑制剂的SAR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号